{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:36:40Z","timestamp":1794875800635,"version":"4.9.1"},"reference-count":244,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ijbiomac.2021.01.076","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T21:17:19Z","timestamp":1610659039000},"page":"524-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":259,"special_numbering":"C","title":["Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs"],"prefix":"10.1016","volume":"172","author":[{"given":"Dharma Rao","family":"Tompa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruldoss","family":"Immanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srimari","family":"Srikanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraboji","family":"Kadhirvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0005","unstructured":"H. Lodish, A. Berk, S.L. Zipursky, P. Matsudaira, D. Baltimore, J. Darnell, Molecular Cell Biology. 4 ed., W.H. Freeman & Co. Ltd, New York, 2000."},{"issue":"9244","key":"10.1016\/j.ijbiomac.2021.01.076_bb0010","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study","volume":"356","author":"Greub","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0015","series-title":"Centers for Disease Control","first-page":"1","author":"CDC, HIV\/AIDs Surveillance Report, US Department of Health and Human Services, Public Health Service","year":"1990"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0020","unstructured":"A.S. Evans, Viral Infections of Humans: Epidemiology and Control, 3 ed., Springer Science & Business Media2013."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0025","series-title":"xPharm: The Comprehensive Pharmacology Reference","first-page":"1","article-title":"Viral replication","author":"Soderstrom","year":"2007"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/B978-0-12-253055-5.50008-6","article-title":"Viral replication","author":"Fenner","year":"1987","journal-title":"Veterinary Virology"},{"issue":"6037","key":"10.1016\/j.ijbiomac.2021.01.076_bb0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/317489a0","article-title":"The hepatitis B virus","volume":"317","author":"Tiollais","year":"1985","journal-title":"Nature"},{"issue":"4715","key":"10.1016\/j.ijbiomac.2021.01.076_bb0040","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.4023707","article-title":"Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution","volume":"229","author":"Rice","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0045","series-title":"Current Topics in Microbiology and Immunology: Volume 105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-69159-1_1","article-title":"Replication strategies of the single stranded RNA viruses of eukaryotes","author":"Strauss","year":"1983"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0050","doi-asserted-by":"crossref","unstructured":"Evaluation of idoxuridine (IDU): (Dendrid, Herplex, Stoxil), JAMA 190(6) (1964) 535\u2013536. doi: https:\/\/doi.org\/10.1001\/jama.1964.03070190055009.","DOI":"10.1001\/jama.1964.03070190055009"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0055","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9394(65)90919-0","article-title":"Treatment of hepatic keratitis with IDU and corticosteroids; report of 105 cases","volume":"60","author":"Thomas","year":"1965","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0060","doi-asserted-by":"crossref","unstructured":"A chronicle on the SARS epidemic, Chinese Law & Government 36(4) (2003) 12\u201315. doi: https:\/\/doi.org\/10.2753\/CLG0009-4609360412.","DOI":"10.2753\/CLG0009-4609360412"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0065","doi-asserted-by":"crossref","unstructured":"J.-F. He, G.-W. Peng, J. Min, D.-W. Yu, W.-J. Liang, S.-Y. Zhang, R.-H. Xu, H.-Y. Zheng, X.-W. Wu, J. Xu, Z.-H. Wang, L. Fang, X. Zhang, H. Li, X.-G. Yan, J.-H. Lu, Z.-H. Hu, J.-C. Huang, Z.-Y. Wan, J.-L. Hou, J.-Y. Lin, H.-D. Song, S.-Y. Wang, X.-J. Zhou, G.-W. Zhang, B.-W. Gu, H.-J. Zheng, X.-L. Zhang, M. He, K. Zheng, B. Wang, G. Fu, X.-N. Wang, S.-J. Chen, Z. Chen, P. Hao, H. Tang, S.-X. Ren, Y. Zhong, Z.-M. Guo, Q. Liu, Y.-G. Miao, X.-Y. Kong, W.-Z. He, Y.-X. Li, C.-I. Wu, G.-P. Zhao, R.W.K. Chiu, S.S.C. Chim, Y.-k. Tong, P.K.S. Chan, J.S. Tam, Y.M.D. Lo, Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China, Science 303(5664) (2004) 1666\u20131669. doi: https:\/\/doi.org\/10.1126\/science.1092002.","DOI":"10.1126\/science.1092002"},{"issue":"7798","key":"10.1016\/j.ijbiomac.2021.01.076_bb0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"10223","key":"10.1016\/j.ijbiomac.2021.01.076_bb0075","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China, Lancet"},{"issue":"24","key":"10.1016\/j.ijbiomac.2021.01.076_bb0080","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMp038194","article-title":"The discovery of HIV as the cause of AIDS","volume":"349","author":"Gallo","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4599","key":"10.1016\/j.ijbiomac.2021.01.076_bb0085","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barre-Sinoussi","year":"1983","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrg1246","article-title":"The causes and consequences of HIV evolution","volume":"5","author":"Rambaut","year":"2004","journal-title":"Nat. Rev. Genet."},{"issue":"20","key":"10.1016\/j.ijbiomac.2021.01.076_bb0095","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3\u2032-Azido-3\u2032-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.01.076_bb0100","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2\u2032,3\u2032-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2\u2032,3\u2032-dideoxythymidine and its 2\u2032,3\u2032-unsaturated derivative (2\u2032,3\u2032-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.01.076_bb0110","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/AAC.31.6.907","article-title":"Inhibitory effect of 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus","volume":"31","author":"Hamamoto","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ijbiomac.2021.01.076_bb0115","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.35.7.1386","article-title":"Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2\u2032-deoxy-3\u2032-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog","volume":"35","author":"Soudeyns","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb0120","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.41.5.1082","article-title":"1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity","volume":"41","author":"Daluge","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0125","doi-asserted-by":"crossref","first-page":"990","DOI":"10.2174\/138161208784139738","article-title":"Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4","volume":"14","author":"Zhou","year":"2008","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.01.076_bb0135","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion","volume":"9","author":"Wild","year":"1993","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.01.076_bb0140","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.01.076_bb0145","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1","volume":"11","author":"Fatkenheuer","year":"2005","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.ijbiomac.2021.01.076_bb0150","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0155","doi-asserted-by":"crossref","unstructured":"S. Raymond, A. Maillard, C. Amiel, G. Peytavin, M.A. Trabaud, D. Desbois, P. Bellecave, C. Delaugerre, C. Soulie, A.G. Marcelin, D. Descamps, J. Izopet, A.A.C.R.S.G. on behalf the, Virological failure of patients on maraviroc-based antiretroviral therapy, J. Antimicrob. Chemother. 70(6) (2015) 1858\u201364. doi: https:\/\/doi.org\/10.1093\/jac\/dkv026.","DOI":"10.1093\/jac\/dkv026"},{"issue":"7","key":"10.1016\/j.ijbiomac.2021.01.076_bb0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40265-018-0907-5","article-title":"Ibalizumab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0165","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.idc.2019.05.006","article-title":"Key principles of antiretroviral pharmacology","volume":"33","author":"Dionne","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"issue":"15","key":"10.1016\/j.ijbiomac.2021.01.076_bb0170","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s40265-018-0993-4","article-title":"Doravirine: first global approval","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"#cr-split#-10.1016\/j.ijbiomac.2021.01.076_bb0175.1","doi-asserted-by":"crossref","unstructured":"R. Talwani, Z. Temesgen, Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection, Drugs of today (Barcelona, Spain: 1998) 56","DOI":"10.1358\/dot.2020.56.2.3109966"},{"key":"#cr-split#-10.1016\/j.ijbiomac.2021.01.076_bb0175.2","doi-asserted-by":"crossref","unstructured":"(2) (2020) 113-124. doi: https:\/\/doi.org\/10.1358\/dot.2020.56.2.3109966.","DOI":"10.1358\/dot.2020.56.2.3109966"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0180","series-title":"Delstrigo (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate) Prescribing Information","author":"Sharp","year":"2018"},{"issue":"12","key":"10.1016\/j.ijbiomac.2021.01.076_bb0185","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb0190","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-018-0896-4","article-title":"Bictegravir: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0213-005X(18)30395-1","article-title":"Symtuza\u00ae in clinical practice","volume":"36","author":"Luis Casado","year":"2018","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"issue":"Suppl. 2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0213-005X(18)30393-8","article-title":"Symtuza\u00ae (DRV\/c\/FTC\/TAF) in the management of treatment-naive HIV-patients","volume":"36","author":"G\u00f3mez Ayerbe","year":"2018","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0205","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1060028018793252","article-title":"HIV clinical updates: new single-tablet regimens","volume":"53","author":"Sebaaly","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40265-019-01247-1","article-title":"Dolutegravir\/lamivudine single-tablet regimen: a review in HIV-1 infection","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0215","unstructured":"RxList, Fulyzaq. https:\/\/www.rxlist.com\/fulyzaq-drug.htm#description."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.01.076_bb0220","first-page":"1351","article-title":"Hepatitis C: diagnosis and treatment","volume":"81","author":"Wilkins","year":"2010","journal-title":"Am. Fam. Physician"},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb0225","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bcp.2014.04.005","article-title":"Current race in the development of DAAs (direct-acting antivirals) against HCV","volume":"89","author":"De Clercq","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb0230","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/rmv.1842","article-title":"Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace","volume":"25","author":"De Clercq","year":"2015","journal-title":"Rev. Med. Virol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.01.076_bb0235","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1021\/jm9015526","article-title":"Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3\/4a protease inhibitor","volume":"53","author":"McCauley","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0240","doi-asserted-by":"crossref","unstructured":"T. McQuaid, C. Savini, S. Seyedkazemi, Sofosbuvir, a significant paradigm change in HCV treatment, Journal of clinical and translational hepatology 3(1) (2015) 27\u201335. doi: 10.14218\/jcth.2014.00041.","DOI":"10.14218\/JCTH.2014.00041"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0245","doi-asserted-by":"crossref","unstructured":"M. Bourliere, J.P. Bronowicki, V. de Ledinghen, C. Hezode, F. Zoulim, P. Mathurin, A. Tran, D.G. Larrey, V. Ratziu, L. Alric, R.H. Hyland, D. Jiang, B. Doehle, P.S. Pang, W.T. Symonds, G.M. Subramanian, J.G. McHutchison, P. Marcellin, F. Habersetzer, D. Guyader, J.D. Grange, V. Loustaud-Ratti, L. Serfaty, S. Metivier, V. Leroy, A. Abergel, S. Pol, Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS), Lancet Infect. Dis. 15(4) (2015) 397\u2013404. doi: https:\/\/doi.org\/10.1016\/S1473-3099(15)70050-2.","DOI":"10.1016\/S1473-3099(15)70050-2"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0250","doi-asserted-by":"crossref","unstructured":"S. Naggie, C. Cooper, M. Saag, K. Workowski, P. Ruane, W.J. Towner, K. Marks, A. Luetkemeyer, R.P. Baden, P.E. Sax, E. Gane, J. Santana-Bagur, L.M. Stamm, J.C. Yang, P. German, H. Dvory-Sobol, L. Ni, P.S. Pang, J.G. McHutchison, C.A. Stedman, J.O. Morales-Ramirez, N. Brau, D. Jayaweera, A.E. Colson, P. Tebas, D.K. Wong, D. Dieterich, M. Sulkowski, I.O.N. Investigators, Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1, N. Engl. J. Med. 373(8) (2015) 705\u201313. doi: https:\/\/doi.org\/10.1056\/NEJMoa1501315.","DOI":"10.1056\/NEJMoa1501315"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0255","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/DDDT.S130945","article-title":"Sofosbuvir\/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure","volume":"11","author":"Mir","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0260","series-title":"FDA Approves Vosevi for Hepatitis C","author":"FDA","year":"2017"},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/fvl-2018-0134","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir in the treatment of chronic hepatitis C infection","volume":"14","author":"Kilaru","year":"2019","journal-title":"Future Virol."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0270","doi-asserted-by":"crossref","unstructured":"J.G. Taylor, S. Zipfel, K. Ramey, R. Vivian, A. Schrier, K.K. Karki, A. Katana, D. Kato, T. Kobayashi, R. Martinez, M. Sangi, D. Siegel, C.V. Tran, Z.Y. Yang, J. Zablocki, C.Y. Yang, Y. Wang, K. Wang, K. Chan, O. Barauskas, G. Cheng, D. Jin, B.E. Schultz, T. Appleby, A.G. Villasenor, J.O. Link, Discovery of the pan-genotypic hepatitis C virus NS3\/4A protease inhibitor voxilaprevir (GS-9857): a component of Vosevi((R)), Bioorg. Med. Chem. Lett. 29(16) (2019) 2428\u20132436. doi: https:\/\/doi.org\/10.1016\/j.bmcl.2019.03.037.","DOI":"10.1016\/j.bmcl.2019.03.037"},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb0275","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00535-015-1120-x","article-title":"Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study","volume":"51","author":"Hayashi","year":"2016","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0280","unstructured":"L. Margusino-Framinan, P. Cid-Silva, A. Mena-de-Cea, I. Rodriguez-Osorio, B. Pernas-Souto, M. Delgado-Blanco, S. Pertega-Diaz, I. Martin-Herranz, A. Castro-Iglesias, Effectiveness and safety of daclatasvir\/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice, Rev. Esp. Quimioter. 32(2) (2019) 137\u2013144."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0285","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12882-019-1631-4","article-title":"Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis-a prospective interventional clinical trial","volume":"20","author":"Cheema","year":"2019","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0290","doi-asserted-by":"crossref","unstructured":"E. Lawitz, E. Gane, B. Pearlman, E. Tam, W. Ghesquiere, D. Guyader, L. Alric, J.P. Bronowicki, L. Lester, W. Sievert, R. Ghalib, L. Balart, F. Sund, M. Lagging, F. Dutko, M. Shaughnessy, P. Hwang, A.Y. Howe, J. Wahl, M. Robertson, E. Barr, B. Haber, Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial, Lancet 385(9973) (2015) 1075\u201386. doi: https:\/\/doi.org\/10.1016\/S0140-6736(14)61795-5.","DOI":"10.1016\/S0140-6736(14)61795-5"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0300","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0305","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J. Hepatol."},{"issue":"15","key":"10.1016\/j.ijbiomac.2021.01.076_bb0310","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0315","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0320","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb0325","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"issue":"25","key":"10.1016\/j.ijbiomac.2021.01.076_bb0330","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0335","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0340","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0345","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jvh.12444","article-title":"Hepatitis B: 50 years after the discovery of Australia antigen","volume":"23","author":"Lok","year":"2016","journal-title":"J. Viral Hepat."},{"issue":"8","key":"10.1016\/j.ijbiomac.2021.01.076_bb0350","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nrmicro2613","article-title":"Influenza A viruses: new research developments","volume":"9","author":"Medina","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3201\/eid1201.051254","article-title":"Influenza pandemics of the 20th century","volume":"12","author":"Kilbourne","year":"2006","journal-title":"Emerg. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ijbiomac.2021.01.076_bb0360","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.arcmed.2009.10.004","article-title":"H1N1 influenza pandemics: comparing the events of 2009 in Mexico with those of 1976 and 1918\u20131919","volume":"40","author":"Franco-Paredes","year":"2009","journal-title":"Arch. Med. Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0365","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbamem.2010.04.015","article-title":"Influenza M2 proton channels","volume":"1808","author":"Pielak","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"31","key":"10.1016\/j.ijbiomac.2021.01.076_bb0370","doi-asserted-by":"crossref","first-page":"7356","DOI":"10.1021\/bi9008837","article-title":"Structure and function of the influenza A M2 proton channel","volume":"48","author":"Cady","year":"2009","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0375","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","article-title":"Characterization of temperature sensitive influenza virus mutants defective in neuraminidase","volume":"61","author":"Palese","year":"1974","journal-title":"Virology"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0380","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fmicb.2019.00039","article-title":"Influenza virus neuraminidase structure and functions","volume":"10","author":"McAuley","year":"2019","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb0385","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jmb.2008.11.022","article-title":"Structure of amantadine-bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in amantadine binding","volume":"385","author":"Cady","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2021.01.076_bb0390","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7107","key":"10.1016\/j.ijbiomac.2021.01.076_bb0395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature05114","article-title":"The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design","volume":"443","author":"Russell","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ijbiomac.2021.01.076_bb0400","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1128\/AAC.47.7.2264-2272.2003","article-title":"Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir","volume":"47","author":"McKimm-Breschkin","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.ijbiomac.2021.01.076_bb0405","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1517\/14656566.2015.1066336","article-title":"Peramivir: an intravenous neuraminidase inhibitor","volume":"16","author":"McLaughlin","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0410","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/jmv.24232","article-title":"Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza","volume":"87","author":"Yoo","year":"2015","journal-title":"J. Med. Virol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0415","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.01.076_bb0420","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/AAC.11.6.946","article-title":"Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate","volume":"11","author":"Eriksson","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0425","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0430","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb0435","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkp274","article-title":"Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells","volume":"64","author":"Smee","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.01.076_bb0440","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/med.21256","article-title":"Highlights in antiviral drug research: antivirals at the horizon","volume":"33","author":"De Clercq","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0445","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: the new influenza drug on the market","volume":"35","author":"O\u2019Hanlon","year":"2019","journal-title":"Curr. Opin. Virol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.01.076_bb0450","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","article-title":"Baloxavir: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0455","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/514600","article-title":"Herpes simplex viruses","volume":"26","author":"Whitley","year":"1998","journal-title":"Clin. Infect. Dis."},{"issue":"9267","key":"10.1016\/j.ijbiomac.2021.01.076_bb0460","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0465","doi-asserted-by":"crossref","unstructured":"D.M. Koelle, A. Wald, Herpes simplex virus: the importance of asymptomatic shedding, J. Antimicrob. Chemother. 45 Suppl T3 (2000) 1\u20138. doi: https:\/\/doi.org\/10.1093\/jac\/45.suppl_4.1.","DOI":"10.1093\/jac\/45.suppl_4.1"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0470","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-3002(59)90597-9","article-title":"Synthesis and biological activities of iododeoxyuridine, an analog of thymidine","volume":"32","author":"Prusoff","year":"1959","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0475","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3181\/00379727-107-26560","article-title":"Plaque inhibition test for detection of specific inhibitors of DNA containing viruses","volume":"107","author":"Herrmann","year":"1961","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"3632","key":"10.1016\/j.ijbiomac.2021.01.076_bb0480","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1126\/science.145.3632.585","article-title":"Therapeutic antiviral action of 5-trifluoromethyl-2\u2032-deoxyuridine in herpes simplex keratitis","volume":"145","author":"Kaufman","year":"1964","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ijbiomac.2021.01.076_bb0485","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","article-title":"Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster","volume":"68","author":"De Clercq","year":"2004","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0490","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl","key":"10.1016\/j.ijbiomac.2021.01.076_bb0495","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/02713689109020379","article-title":"Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents","volume":"10","author":"Maudgal","year":"1991","journal-title":"Curr. Eye Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0500","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1067\/mjd.2001.116215","article-title":"Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial","volume":"45","author":"Sacks","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0505","first-page":"409","article-title":"Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology","volume":"4","author":"Modi","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0510","doi-asserted-by":"crossref","unstructured":"M.A. Pue, L.Z. Benet, Pharmacokinetics of famciclovir in man, Antivir. Chem. Chemother. 4(6_suppl) (1993) 47\u201355. doi: https:\/\/doi.org\/10.1177\/09563202930040s602.","DOI":"10.1177\/09563202930040S602"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0515","doi-asserted-by":"crossref","unstructured":"M. Reitano, S. Tyring, W. Lang, C. Thoming, A.M. Worm, S. Borelli, L.O. Chambers, J.M. Robinson, L. Corey, Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International valaciclovir HSV study group, J. Infect. Dis. 178(3) (1998) 603\u201310. doi: https:\/\/doi.org\/10.1086\/515385.","DOI":"10.1086\/515385"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0520","doi-asserted-by":"crossref","unstructured":"E.-M. de Villiers, C. Fauquet, T.R. Broker, H.-U. Bernard, H. zur Hausen, Classification of papillomaviruses, Virology 324(1) (2004) 17\u201327. doi: https:\/\/doi.org\/10.1016\/j.virol.2004.03.033.","DOI":"10.1016\/j.virol.2004.03.033"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0525","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev.mi.48.100194.002235","article-title":"Human papillomaviruses","volume":"48","author":"Zur Hausen","year":"1994","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0530","unstructured":"K.A. Workowski, G.A. Bolan, C. Centers for Disease, Prevention, Sexually transmitted diseases treatment guidelines, 2015, MMWR Recomm. Rep. 64(RR-03) (2015) 1\u2013137."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0535","doi-asserted-by":"crossref","unstructured":"M. Durst, L. Gissmann, H. Ikenberg, H. zur Hausen, A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions, Proc. Natl. Acad. Sci. U. S. A. 80(12) (1983) 3812\u20135. doi: https:\/\/doi.org\/10.1073\/pnas.80.12.3812.","DOI":"10.1073\/pnas.80.12.3812"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0540","doi-asserted-by":"crossref","unstructured":"S. Tyring, L. Edwards, L.K. Cherry, W.M. Ramsdell, S. Kotner, M.D. Greenberg, J.C. Vance, G. Barnum, S.H. Dromgoole, F.P. Killey, T. Toter, Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts, Arch. Dermatol. 134(1) (1998) 33\u20138. doi: https:\/\/doi.org\/10.1001\/archderm.134.1.33.","DOI":"10.1001\/archderm.134.1.33"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0545","unstructured":"M.D. Greenberg, L.H. Rutledge, R. Reid, N.R. Berman, S.L. Precop, R.K. Elswick, Jr., A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women, Obstet. Gynecol. 77(5) (1991) 735\u20139."},{"issue":"3 Suppl","key":"10.1016\/j.ijbiomac.2021.01.076_bb0550","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1067\/S0002-9378(03)00789-0","article-title":"Genital and perianal warts: new treatment opportunities for human papillomavirus infection","volume":"189","author":"Gunter","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb0555","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.42.4.789","article-title":"Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts","volume":"42","author":"Beutner","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2 Pt 1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0560","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0190-9622(98)70243-9","article-title":"Treatment of genital warts with an immune-response modifier (imiquimod)","volume":"38","author":"Beutner","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"issue":"Suppl. 2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0565","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1086\/342109","article-title":"External genital warts: diagnosis, treatment, and prevention","volume":"35","author":"Wiley","year":"2002","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0570","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nbt1008-1077","article-title":"New therapies from old medicines","volume":"26","author":"Chen","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.01.076_bb0575","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/AOG.0b013e3181719b60","article-title":"Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial","volume":"111","author":"Tatti","year":"2008","journal-title":"Obstet. Gynecol."},{"issue":"9181","key":"10.1016\/j.ijbiomac.2021.01.076_bb0580","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(99)80040-3","article-title":"Respiratory syncytial virus infection","volume":"354","author":"Simoes","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0585","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/ajhp\/57.3.259","article-title":"Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection","volume":"57","author":"Robinson","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb0590","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/14787210.3.5.719","article-title":"Palivizumab in the prophylaxis of respiratory syncytial virus infection","volume":"3","author":"Cardenas","year":"2005","journal-title":"Expert Rev. Anti-Infect. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0595","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00003495-199958020-00009","article-title":"Palivizumab","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0600","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0166-3542(85)90012-9","article-title":"Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis","volume":"5","author":"Wray","year":"1985","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0605","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-9071(199609)50:1<31::AID-JMV7>3.0.CO;2-U","article-title":"Human cytomegalovirus glycoprotein B genotypes in renal transplant recipients","volume":"50","author":"Vogelberg","year":"1996","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0610","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/0042-6822(92)90771-G","article-title":"Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus","volume":"188","author":"Chou","year":"1992","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0615","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","article-title":"Ganciclovir","volume":"335","author":"Crumpacker","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0620","doi-asserted-by":"crossref","unstructured":"D.W. Kimberlin, P.M. Jester, P.J. Sanchez, A. Ahmed, R. Arav-Boger, M.G. Michaels, N. Ashouri, J.A. Englund, B. Estrada, R.F. Jacobs, J.R. Romero, S.K. Sood, M.S. Whitworth, M.J. Abzug, M.T. Caserta, S. Fowler, J. Lujan-Zilbermann, G.A. Storch, R.L. DeBiasi, J.Y. Han, A. Palmer, L.B. Weiner, J.A. Bocchini, P.H. Dennehy, A. Finn, P.D. Griffiths, S. Luck, K. Gutierrez, N. Halasa, J. Homans, A.L. Shane, M. Sharland, K. Simonsen, J.A. Vanchiere, C.R. Woods, D.L. Sabo, I. Aban, H. Kuo, S.H. James, M.N. Prichard, J. Griffin, D. Giles, E.P. Acosta, R.J. Whitley, Valganciclovir for symptomatic congenital cytomegalovirus disease, N. Engl. J. Med. 372(10) (2015) 933\u201343. doi: https:\/\/doi.org\/10.1056\/NEJMoa1404599.","DOI":"10.1056\/NEJMoa1404599"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0625","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.00561-13","article-title":"Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens","volume":"58","author":"Minces","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3\u20134","key":"10.1016\/j.ijbiomac.2021.01.076_bb0630","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"de Smet","year":"1999","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0635","first-page":"288","article-title":"Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc\/CIBA vision","volume":"3","author":"Orr","year":"2001","journal-title":"Curr. Opin. Mol. Ther."},{"key":"#cr-split#-10.1016\/j.ijbiomac.2021.01.076_bb0640.1","doi-asserted-by":"crossref","unstructured":"L.R. Grillone, R. Lanz, Fomivirsen, Drugs of today (Barcelona, Spain : 1998) 37","DOI":"10.1358\/dot.2001.37.4.620590"},{"key":"#cr-split#-10.1016\/j.ijbiomac.2021.01.076_bb0640.2","doi-asserted-by":"crossref","unstructured":"(4) (2001) 245-255. doi: https:\/\/doi.org\/10.1358\/dot.2001.37.4.620590.","DOI":"10.1358\/dot.2001.37.4.620590"},{"issue":"20","key":"10.1016\/j.ijbiomac.2021.01.076_bb0645","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0650","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13543784.2017.1274733","article-title":"Letermovir for the management of cytomegalovirus infection","volume":"26","author":"Bowman","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0655","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0660","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0665","doi-asserted-by":"crossref","unstructured":"R.J. Whitley, L.T. Ch'ien, R. Dolin, G.J. Galasso, C.A. Alford, Jr., Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study, N. Engl. J. Med. 294(22) (1976) 1193\u20139. doi: https:\/\/doi.org\/10.1056\/NEJM197605272942201.","DOI":"10.1056\/NEJM197605272942201"},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb0670","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/infdis\/147.4.737","article-title":"Evaluation of Varicella-Zoster immune globulin: protection of immunosuppressed children after household exposure to varicella","volume":"147","author":"Zaia","year":"1983","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0675","doi-asserted-by":"crossref","unstructured":"CDC, FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella, MMWR Morb. Mortal. Wkly. Rep. 61(12) (2012) 212.","DOI":"10.1111\/j.1600-6143.2012.04257.x"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0680","unstructured":"CDC, Updated recommendations for use of VariZIG-United States, 2013, MMWR Morb. Mortal. Wkly. Rep. 62(28) (2013) 574\u2013576."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0685","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11262-009-0404-8","article-title":"An update on swine-origin influenza virus A\/H1N1: a review","volume":"39","author":"Schnitzler","year":"2009","journal-title":"Virus Genes"},{"issue":"7249","key":"10.1016\/j.ijbiomac.2021.01.076_bb0690","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature08157","article-title":"Emergence and pandemic potential of swine-origin H1N1 influenza virus","volume":"459","author":"Neumann","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0695","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.05012-11","article-title":"Two years after pandemic influenza A\/2009\/H1N1: what have we learned?","volume":"25","author":"Cheng","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0700","author":"CDC"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb0705","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.aogh.2015.08.014","article-title":"Treatment and prevention of pandemic H1N1 influenza","volume":"81","author":"Rewar","year":"2015","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0710","author":"FDA"},{"issue":"Suppl. 3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0715","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/infdis\/jiw207","article-title":"Discovery and description of Ebola Zaire virus in 1976 and relevance to the West African epidemic during 2013\u20132016","volume":"214","author":"Breman","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0720","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0725","doi-asserted-by":"crossref","unstructured":"D. Sissoko, C. Laouenan, E. Folkesson, A.-B. M'Lebing, A.-H. Beavogui, S. Baize, A.-M. Camara, P. Maes, S. Shepherd, C. Danel, S. Carazo, M.N. Conde, J.-L. Gala, G. Colin, H. Savini, J.A. Bore, F. Le Marcis, F.R. Koundouno, F. Petitjean, M.-C. Lamah, S. Diederich, A. Tounkara, G. Poelart, E. Berbain, J.-M. Dindart, S. Duraffour, A. Lefevre, T. Leno, O. Peyrouset, L. Irenge, N.F. Bangoura, R. Palich, J. Hinzmann, A. Kraus, T.S. Barry, S. Berette, A. Bongono, M.S. Camara, V. Chanfreau Munoz, L. Doumbouya, H. Souley, P.M. Kighoma, F.R. Koundouno, L. R\u00e9n\u00e9, C.M. Loua, V. Massala, K. Moumouni, C. Provost, N. Samake, C. Sekou, A. Soumah, I. Arnould, M.S. Komano, L. Gustin, C. Berutto, D. Camara, F.S. Camara, J. Colpaert, L. Delamou, L. Jansson, E. Kourouma, M. Loua, K. Malme, E. Manfrin, A. Maomou, A. Milinouno, S. Ombelet, A.Y. Sidiboun, I. Verreckt, P. Yombouno, A. Bocquin, C. Carbonnelle, T. Carmoi, P. Frange, S. Mely, V.-K. Nguyen, D. Pannetier, A.-M. Taburet, J.-M. Treluyer, J. Kolie, R. Moh, M.C. Gonzalez, E. Kuisma, B. Liedigk, D. Ngabo, M. Rudolf, R. Thom, R. Kerber, M. Gabriel, A. Di Caro, R. W\u00f6lfel, J. Badir, M. Bentahir, Y. Deccache, C. Dumont, J.-F. Durant, K. El Bakkouri, M. Gasasira Uwamahoro, B. Smits, N. Toufik, S. Van Cauwenberghe, K. Ezzedine, E. Dortenzio, L. Pizarro, A. Etienne, J. Guedj, A. Fizet, E. Barte de Sainte Fare, B. Murgue, T. Tran-Minh, C. Rapp, P. Piguet, M. Poncin, B. Draguez, T. Allaford Duverger, S. Barbe, G. Baret, I. Defourny, M. Carroll, H. Raoul, A. Augier, S.P. Eholie, Y. Yazdanpanah, C. Levy-Marchal, A. Antierrens, M. Van Herp, S. G\u00fcnther, X. de Lamballerie, S. Ke\u00efta, F. Mentre, X. Anglaret, D. Malvy, J.S. Group, Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea, PLoS Med. 13(3) (2016) e1001967. doi: https:\/\/doi.org\/10.1371\/journal.pmed.1001967.","DOI":"10.1371\/journal.pmed.1001967"},{"issue":"15","key":"10.1016\/j.ijbiomac.2021.01.076_bb0730","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"Davey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0735","doi-asserted-by":"crossref","unstructured":"T.K. Warren, R. Jordan, M.K. Lo, A.S. Ray, R.L. Mackman, V. Soloveva, D. Siegel, M. Perron, R. Bannister, H.C. Hui, N. Larson, R. Strickley, J. Wells, K.S. Stuthman, S.A. Van Tongeren, N.L. Garza, G. Donnelly, A.C. Shurtleff, C.J. Retterer, D. Gharaibeh, R. Zamani, T. Kenny, B.P. Eaton, E. Grimes, L.S. Welch, L. Gomba, C.L. Wilhelmsen, D.K. Nichols, J.E. Nuss, E.R. Nagle, J.R. Kugelman, G. Palacios, E. Doerffler, S. Neville, E. Carra, M.O. Clarke, L. Zhang, W. Lew, B. Ross, Q. Wang, K. Chun, L. Wolfe, D. Babusis, Y. Park, K.M. Stray, I. Trancheva, J.Y. Feng, O. Barauskas, Y. Xu, P. Wong, M.R. Braun, M. Flint, L.K. McMullan, S.S. Chen, R. Fearns, S. Swaminathan, D.L. Mayers, C.F. Spiropoulou, W.A. Lee, S.T. Nichol, T. Cihlar, S. Bavari, Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, Nature 531(7594) (2016) 381\u20135. doi: https:\/\/doi.org\/10.1038\/nature17180.","DOI":"10.1038\/nature17180"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0740","doi-asserted-by":"crossref","unstructured":"S. Mulangu, L.E. Dodd, R.T. Davey, Jr., O. Tshiani Mbaya, M. Proschan, D. Mukadi, M. Lusakibanza Manzo, D. Nzolo, A. Tshomba Oloma, A. Ibanda, R. Ali, S. Coulibaly, A.C. Levine, R. Grais, J. Diaz, H.C. Lane, J.J. Muyembe-Tamfum, P.W. Group, B. Sivahera, M. Camara, R. Kojan, R. Walker, B. Dighero-Kemp, H. Cao, P. Mukumbayi, P. Mbala-Kingebeni, S. Ahuka, S. Albert, T. Bonnett, I. Crozier, M. Duvenhage, C. Proffitt, M. Teitelbaum, T. Moench, J. Aboulhab, K. Barrett, K. Cahill, K. Cone, R. Eckes, L. Hensley, B. Herpin, E. Higgs, J. Ledgerwood, J. Pierson, M. Smolskis, Y. Sow, J. Tierney, S. Sivapalasingam, W. Holman, N. Gettinger, D. Vallee, J. Nordwall, P.C.S. Team, A randomized, controlled trial of Ebola virus disease therapeutics, N. Engl. J. Med. 381(24) (2019) 2293\u20132303. doi: https:\/\/doi.org\/10.1056\/NEJMoa1910993.","DOI":"10.1056\/NEJMoa1910993"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0745","author":"CDC"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0750","unstructured":"FDA, U.S. Food and Drug Administration. First FDA-approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response, 2019."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0755","author":"CDC"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0760","author":"NIAID"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb0765","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/irv.12563","article-title":"Human coronaviruses and other respiratory infections in young adults on a university campus: prevalence, symptoms, and shedding","volume":"12","author":"Davis","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"issue":"9393","key":"10.1016\/j.ijbiomac.2021.01.076_bb0770","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","article-title":"Epidemiological and aetiological studies of patients with severe acute respiratory syndrome (SARS) from Guangdong in February 2003","volume":"362","author":"Zhong","year":"2003","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ijbiomac.2021.01.076_bb0775","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ijbiomac.2021.01.076_bb0780","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra032498","article-title":"The severe acute respiratory syndrome","volume":"349","author":"Peiris","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijbiomac.2021.01.076_bb0785","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa030685","article-title":"A major outbreak of severe acute respiratory syndrome in Hong Kong","volume":"348","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijbiomac.2021.01.076_bb0790","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa030634","article-title":"Identification of severe acute respiratory syndrome in Canada","volume":"348","author":"Poutanen","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0795","unstructured":"CDC, Update: outbreak of severe acute respiratory syndrome-worldwide, 2003, MMWR Morb. Mortal. Wkly. Rep. 52(12) (2003) 241\u20136, 248."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.01.076_bb0800","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.3201\/eid1011.040797_02","article-title":"SARS, the first pandemic of the 21st century","volume":"10","author":"LeDuc","year":"2004","journal-title":"Emerging Infect. Dis."},{"issue":"20","key":"10.1016\/j.ijbiomac.2021.01.076_bb0805","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijbiomac.2021.01.076_bb0810","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9380","key":"10.1016\/j.ijbiomac.2021.01.076_bb0815","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(03)13967-0","article-title":"Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome","volume":"362","author":"Kuiken","year":"2003","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ijbiomac.2021.01.076_bb0820","doi-asserted-by":"crossref","first-page":"11892","DOI":"10.1128\/JVI.79.18.11892-11900.2005","article-title":"Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms","volume":"79","author":"Kan","year":"2005","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2021.01.076_bb0825","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3201\/eid1112.041293","article-title":"SARS-CoV infection in a restaurant from palm civet","volume":"11","author":"Wang","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0830","author":"Gompf"},{"issue":"14","key":"10.1016\/j.ijbiomac.2021.01.076_bb0835","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1128\/JVI.01244-13","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group","volume":"87","author":"de Groot","year":"2013","journal-title":"J. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0840","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.26719\/2013.19.supp1.S12","article-title":"Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation","volume":"19","author":"Hijawi","year":"2013","journal-title":"East Mediterr. Health J."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0845","author":"WHO"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0850","author":"WHO"},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.01.076_bb0855","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0860","doi-asserted-by":"crossref","unstructured":"C.B. Reusken, B.L. Haagmans, M.A. M\u00fcller, C. Gutierrez, G.J. Godeke, B. Meyer, D. Muth, V.S. Raj, L. Smits-De Vries, V.M. Corman, J.F. Drexler, S.L. Smits, Y.E. El Tahir, R. De Sousa, J. van Beek, N. Nowotny, K. van Maanen, E. Hidalgo-Hermoso, B.J. Bosch, P. Rottier, A. Osterhaus, C. Gort\u00e1zar-Schmidt, C. Drosten, M.P. Koopmans, Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study, Lancet Infect. Dis. 13(10) (2013) 859\u201366. doi: https:\/\/doi.org\/10.1016\/s1473-3099(13)70164-6.","DOI":"10.1016\/S1473-3099(13)70164-6"},{"issue":"26","key":"10.1016\/j.ijbiomac.2021.01.076_bb0865","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1401505","article-title":"Evidence for camel-to-human transmission of MERS coronavirus","volume":"370","author":"Azhar","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0870","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.chom.2014.08.009","article-title":"Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26","volume":"16","author":"Wang","year":"2014","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb0875","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1306742","article-title":"Hospital outbreak of Middle East respiratory syndrome coronavirus","volume":"369","author":"Assiri","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ijbiomac.2021.01.076_bb0880","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/cid\/ciu359","article-title":"Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description","volume":"59","author":"Al-Abdallat","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"26","key":"10.1016\/j.ijbiomac.2021.01.076_bb0885","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1303729","article-title":"Family cluster of Middle East respiratory syndrome coronavirus infections","volume":"368","author":"Memish","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0890","doi-asserted-by":"crossref","unstructured":"T.P. Sheahan, A.C. Sims, R.L. Graham, V.D. Menachery, L.E. Gralinski, J.B. Case, S.R. Leist, K. Pyrc, J.Y. Feng, I. Trantcheva, R. Bannister, Y. Park, D. Babusis, M.O. Clarke, R.L. Mackman, J.E. Spahn, C.A. Palmiotti, D. Siegel, A.S. Ray, T. Cihlar, R. Jordan, M.R. Denison, R.S. Baric, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci. Transl. Med. 9(396) (2017) eaal3653. doi: https:\/\/doi.org\/10.1126\/scitranslmed.aal3653.","DOI":"10.1126\/scitranslmed.aal3653"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0895","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0900","doi-asserted-by":"crossref","unstructured":"M.L. Agostini, E.L. Andres, A.C. Sims, R.L. Graham, T.P. Sheahan, X. Lu, E.C. Smith, J.B. Case, J.Y. Feng, R. Jordan, A.S. Ray, T. Cihlar, D. Siegel, R.L. Mackman, M.O. Clarke, R.S. Baric, M.R. Denison, Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease, mBio 9(2) (2018) e00221\u201318. doi: https:\/\/doi.org\/10.1128\/mBio.00221-18.","DOI":"10.1128\/mBio.00221-18"},{"issue":"27","key":"10.1016\/j.ijbiomac.2021.01.076_bb0905","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small molecules targeting severe acute respiratory syndrome human coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0910","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.ijbiomac.2021.01.076_bb0915","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb0920","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","article-title":"Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir. Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.01.076_bb0925","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/civ1020","article-title":"Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea","volume":"62","author":"Bin","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0930","doi-asserted-by":"crossref","unstructured":"Y.M. Arabi, A. Alothman, H.H. Balkhy, A. Al-Dawood, S. AlJohani, S. Al Harbi, S. Kojan, M. Al Jeraisy, A.M. Deeb, A.M. Assiri, F. Al-Hameed, A. AlSaedi, Y. Mandourah, G.A. Almekhlafi, N.M. Sherbeeni, F.E. Elzein, J. Memon, Y. Taha, A. Almotairi, K.A. Maghrabi, I. Qushmaq, A. Al Bshabshe, A. Kharaba, S. Shalhoub, J. Jose, R.A. Fowler, F.G. Hayden, M.A. Hussein, Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial, Trials 19(1) (2018) 81. doi: https:\/\/doi.org\/10.1186\/s13063-017-2427-0.","DOI":"10.1186\/s13063-017-2427-0"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0935","doi-asserted-by":"crossref","unstructured":"Y.M. Arabi, A.Y. Asiri, A.M. Assiri, H.A. Aziz Jokhdar, A. Alothman, H.H. Balkhy, S. AlJohani, S. Al Harbi, S. Kojan, M. Al Jeraisy, A.M. Deeb, Z.A. Memish, S. Ghazal, S. Al Faraj, F. Al-Hameed, A. AlSaedi, Y. Mandourah, G.A. Al Mekhlafi, N.M. Sherbeeni, F.E. Elzein, A. Almotairi, A. Al Bshabshe, A. Kharaba, J. Jose, A. Al Harthy, M. Al Sulaiman, A. Mady, R.A. Fowler, F.G. Hayden, A. Al-Dawood, M. Abdelzaher, W. Bajhmom, M.A. Hussein, Treatment of Middle East respiratory syndrome with a combination of lopinavir\/ritonavir and interferon-\u03b21b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial, Trials 21(1) (2020) 8. doi: https:\/\/doi.org\/10.1186\/s13063-019-3846-x.","DOI":"10.1186\/s13063-019-3846-x"},{"issue":"23","key":"10.1016\/j.ijbiomac.2021.01.076_bb0940","doi-asserted-by":"crossref","first-page":"13769","DOI":"10.1128\/JVI.02232-14","article-title":"Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness","volume":"88","author":"Sui","year":"2014","journal-title":"J. Virol."},{"issue":"33","key":"10.1016\/j.ijbiomac.2021.01.076_bb0945","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0950","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antivir. Res."},{"issue":"17","key":"10.1016\/j.ijbiomac.2021.01.076_bb0955","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.ijbiomac.2021.01.076_bb0960","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1086\/382597","article-title":"Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-\u03b1","volume":"189","author":"Str\u00f6her","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb0965","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/srep01686","article-title":"Inhibition of novel \u03b2 coronavirus replication by a combination of interferon-\u03b12b and ribavirin","volume":"3","author":"Falzarano","year":"2013","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb0970","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm1001","article-title":"Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques","volume":"10","author":"Haagmans","year":"2004","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0975","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-\u03b12b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2021.01.076_bb0980","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.01.076_bb0985","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0990","unstructured":"WHO, Coronavirus disease (COVID-19) pandemic. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. (Accessed 8 January 2021)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb0995","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","article-title":"Discovery and development of safe-in-man broad-spectrum antiviral agents","volume":"93","author":"Andersen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb1000","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.01.076_bb1005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb1010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"issue":"15","key":"10.1016\/j.ijbiomac.2021.01.076_bb1015","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1020","doi-asserted-by":"crossref","unstructured":"J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, E. Hohmann, H.Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R.W. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T.F. Patterson, R. Paredes, D.A. Sweeney, W.R. Short, G. Touloumi, D.C. Lye, N. Ohmagari, M.-d. Oh, G.M. Ruiz-Palacios, T. Benfield, G. F\u00e4tkenheuer, M.G. Kortepeter, R.L. Atmar, C.B. Creech, J. Lundgren, A.G. Babiker, S. Pett, J.D. Neaton, T.H. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, H.C. Lane, Remdesivir for the treatment of Covid-19 \u2014 final report, N. Engl. J. Med. 383(19) (2020) 1813\u20131826. doi: https:\/\/doi.org\/10.1056\/NEJMoa2007764.","DOI":"10.1056\/NEJMoa2007764"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1025","doi-asserted-by":"crossref","unstructured":"J. Grein, N. Ohmagari, D. Shin, G. Diaz, E. Asperges, A. Castagna, T. Feldt, G. Green, M.L. Green, F.-X. Lescure, E. Nicastri, R. Oda, K. Yo, E. Quiros-Roldan, A. Studemeister, J. Redinski, S. Ahmed, J. Bernett, D. Chelliah, D. Chen, S. Chihara, S.H. Cohen, J. Cunningham, A. D'Arminio Monforte, S. Ismail, H. Kato, G. Lapadula, E. L'Her, T. Maeno, S. Majumder, M. Massari, M. Mora-Rillo, Y. Mutoh, D. Nguyen, E. Verweij, A. Zoufaly, A.O. Osinusi, A. DeZure, Y. Zhao, L. Zhong, A. Chokkalingam, E. Elboudwarej, L. Telep, L. Timbs, I. Henne, S. Sellers, H. Cao, S.K. Tan, L. Winterbourne, P. Desai, R. Mera, A. Gaggar, R.P. Myers, D.M. Brainard, R. Childs, T. Flanigan, Compassionate use of remdesivir for patients with severe Covid-19, N. Engl. J. Med. 382(24) (2020) 2327\u20132336. doi: https:\/\/doi.org\/10.1056\/NEJMoa2007016.","DOI":"10.1056\/NEJMoa2007016"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1030","unstructured":"Gilead, Gilead announces results from phase 3 trial of remdesivir in patients with moderate COVID-19, 2020."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1035","unstructured":"H. Balfour, Researchers identify a potential remdesivir resistance mechanism in SARS-CoV-2. https:\/\/www.drugtargetreview.com\/news\/73959\/researchers-identify-a-potential-remdesivir-resistance-mechanism-in-sars-cov-2\/#:~:text=Researchers%20have%20examined%20how%20Ebola,for%20these%20specific%20resistance%20mutations. (Accessed 8 January 8 2021)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1040","doi-asserted-by":"crossref","unstructured":"A.K. Padhi, R. Shukla, P. Saudagar, T. Tripathi, High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance, iScience (2020) 101992. doi: https:\/\/doi.org\/10.1016\/j.isci.2020.101992.","DOI":"10.1101\/2020.06.27.174896"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1045","doi-asserted-by":"crossref","unstructured":"Repurposed antiviral drugs for Covid-19 \u2014 interim WHO Solidarity Trial results, (2020) doi: https:\/\/doi.org\/10.1056\/NEJMoa2023184.","DOI":"10.1056\/NEJMoa2023184"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb1050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb1055","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41423-020-0385-z","article-title":"Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.01.076_bb1060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1065","series-title":"Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig, bioRxiv","author":"Lei","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1070","doi-asserted-by":"crossref","unstructured":"R.L. Kruse, Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China, F1000Res 9 (2020) 72. doi: 10.12688\/f1000research.22211.2.","DOI":"10.12688\/f1000research.22211.2"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1075","unstructured":"ClinicalTrials.gov, Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04287686. (Accessed 30 June 2020)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1080","doi-asserted-by":"crossref","unstructured":"M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kr\u00fcger, T. Herrler, S. Erichsen, T.S. Schiergens, G. Herrler, N.-H. Wu, A. Nitsche, M.A. M\u00fcller, C. Drosten, S. P\u00f6hlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181(2) (2020) 271\u2013280.e8. doi: https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","DOI":"10.1016\/j.cell.2020.02.052"},{"issue":"8","key":"10.1016\/j.ijbiomac.2021.01.076_bb1085","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/JVI.02705-14","article-title":"AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets","volume":"89","author":"Neveu","year":"2015","journal-title":"J. Virol."},{"issue":"10223","key":"10.1016\/j.ijbiomac.2021.01.076_bb1090","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.01.076_bb1095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"ChemBioChem"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.01.076_bb1100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41392-020-0127-9","article-title":"Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia","volume":"5","author":"Zhou","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1105","doi-asserted-by":"crossref","unstructured":"P. Horby, W.S. Lim, J. Emberson, M. Mafham, J. Bell, L. Linsell, N. Staplin, C. Brightling, A. Ustianowski, E. Elmahi, B. Prudon, C. Green, T. Felton, D. Chadwick, K. Rege, C. Fegan, L.C. Chappell, S.N. Faust, T. Jaki, K. Jeffery, A. Montgomery, K. Rowan, E. Juszczak, J.K. Baillie, R. Haynes, M.J. Landray, Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report, medRxiv (2020) 2020.06.22.20137273. doi: https:\/\/doi.org\/10.1101\/2020.06.22.20137273.","DOI":"10.1101\/2020.06.22.20137273"},{"issue":"7813","key":"10.1016\/j.ijbiomac.2021.01.076_bb1110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/d41586-020-01824-5","article-title":"Coronavirus breakthrough: dexamethasone is first drug shown to save lives","volume":"582","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1115","unstructured":"ClinicalTrials.gov, Efficacy and safety of corticosteroids in COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04273321. (Accessed 30 June 2020)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1120","doi-asserted-by":"crossref","unstructured":"D.E. Gordon, G.M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K.M. White, M.J. O'Meara, V.V. Rezelj, J.Z. Guo, D.L. Swaney, T.A. Tummino, R. H\u00fcttenhain, R.M. Kaake, A.L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B.J. Polacco, H. Braberg, J.M. Fabius, M. Eckhardt, M. Soucheray, M.J. Bennett, M. Cakir, M.J. McGregor, Q. Li, B. Meyer, F. Roesch, T. Vallet, A. Mac Kain, L. Miorin, E. Moreno, Z.Z.C. Naing, Y. Zhou, S. Peng, Y. Shi, Z. Zhang, W. Shen, I.T. Kirby, J.E. Melnyk, J.S. Chorba, K. Lou, S.A. Dai, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, J. Lyu, C.J.P. Mathy, T. Perica, K.B. Pilla, S.J. Ganesan, D.J. Saltzberg, R. Rakesh, X. Liu, S.B. Rosenthal, L. Calviello, S. Venkataramanan, J. Liboy-Lugo, Y. Lin, X.-P. Huang, Y. Liu, S.A. Wankowicz, M. Bohn, M. Safari, F.S. Ugur, C. Koh, N.S. Savar, Q.D. Tran, D. Shengjuler, S.J. Fletcher, M.C. O'Neal, Y. Cai, J.C.J. Chang, D.J. Broadhurst, S. Klippsten, P.P. Sharp, N.A. Wenzell, D. Kuzuoglu-Ozturk, H.-Y. Wang, R. Trenker, J.M. Young, D.A. Cavero, J. Hiatt, T.L. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, R.M. Stroud, A.D. Frankel, O.S. Rosenberg, K.A. Verba, D.A. Agard, M. Ott, M. Emerman, N. Jura, M. von Zastrow, E. Verdin, A. Ashworth, O. Schwartz, C. d'Enfert, S. Mukherjee, M. Jacobson, H.S. Malik, D.G. Fujimori, T. Ideker, C.S. Craik, S.N. Floor, J.S. Fraser, J.D. Gross, A. Sali, B.L. Roth, D. Ruggero, J. Taunton, T. Kortemme, P. Beltrao, M. Vignuzzi, A. Garc\u00eda-Sastre, K.M. Shokat, B.K. Shoichet, N.J. Krogan, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature 583(7816) (2020) 459\u2013468. doi: https:\/\/doi.org\/10.1038\/s41586-020-2286-9.","DOI":"10.1038\/s41586-020-2286-9"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1125","unstructured":"ClinicalTrials.gov, Efficacy and safety of Darunavir and Cobicistat for treatment of COVID-19 (DC-COVID-19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04252274?term=DARUNAVIR&draw=2&rank=4. (Accessed 30 June 2020)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1130","unstructured":"ClinicalTrials.gov, Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04310228?term=tocilizumab&cond=covid-19+OR+coronavirus&draw=2. (Accessed 30 June 2020)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1135","unstructured":"ClinicalTrials.gov, A prospective\/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04255017?cond=2019-ncov&draw=2. (Accessed 30 June 2020)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1140","unstructured":"ClinicalTrials.gov, Tocilizumab for SARS-CoV2 (COVID-19) severe pneumonitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315480?term=tocilizumab&cond=covid-19+OR+coronavirus&draw=2. (Accessed 30 June 2020)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1145","unstructured":"ClinicalTrials.gov, COVID-19. https:\/\/clinicaltrials.gov\/ct2\/results?cond=COVID-19. (Accessed 30 June 2020)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1150","author":"Craven"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1155","doi-asserted-by":"crossref","unstructured":"F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G. P\u00e9rez Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, W.V. Kalina, D. Cooper, R.W. Frenck, L.L. Hammitt, \u00d6. T\u00fcreci, H. Nell, A. Schaefer, S. \u00dcnal, D.B. Tresnan, S. Mather, P.R. Dormitzer, U. \u015eahin, K.U. Jansen, W.C. Gruber, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, 383(27) (2020) 2603\u20132615. doi: https:\/\/doi.org\/10.1056\/NEJMoa2034577.","DOI":"10.1056\/NEJMoa2034577"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1160","doi-asserted-by":"crossref","unstructured":"L.R. Baden, H.M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S.A. Spector, N. Rouphael, C.B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B.S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, (2020) doi: https:\/\/doi.org\/10.1056\/NEJMoa2035389.","DOI":"10.1056\/NEJMoa2035389"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1165","author":"Palagin"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1170","author":"Palagin"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1175","unstructured":"Chinese Covid vaccine CoronaVac 78% effective in Brazil trials, claim officials. https:\/\/www.indiatoday.in\/coronavirus-outbreak\/story\/chinese-covid-vaccine-coronavac-78-effective-in-brazil-trials-claim-officials-1756958-2021-01-08. (Accessed 8 January 2021)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1180","series-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial, The Lancet Infectious Diseases","author":"Zhang","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1185","unstructured":"ClinicalTrials.gov, Investigating a vaccine against COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04400838. (Accessed 8 January 2021)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1190","unstructured":"M. Voysey, S.A.C. Clemens, S.A. Madhi, L.Y. Weckx, P.M. Folegatti, P.K. Aley, B. Angus, V.L. Baillie, S.L. Barnabas, Q.E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A.M. Collins, R. Colin-Jones, C.L. Cutland, T.C. Darton, K. Dheda, C.J.A. Duncan, K.R.W. Emary, K.J. Ewer, L. Fairlie, S.N. Faust, S. Feng, D.M. Ferreira, A. Finn, A.L. Goodman, C.M. Green, C.A. Green, P.T. Heath, C. Hill, H. Hill, I. Hirsch, S.H.C. Hodgson, A. Izu, S. Jackson, D. Jenkin, C.C.D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A.M. Lawrie, A. Lelliott, V. Libri, P.J. Lillie, R. Mallory, A.V.A. Mendes, E.P. Milan, A.M. Minassian, A. McGregor, H. Morrison, Y.F. Mujadidi, A. Nana, P.J. O'Reilly, S.D. Padayachee, A. Pittella, E. Plested, K.M. Pollock, M.N. Ramasamy, S. Rhead, A.V. Schwarzbold, N. Singh, A. Smith, R. Song, M.D. Snape, E. Sprinz, R.K. Sutherland, R. Tarrant, E.C. Thomson, M.E. T\u00f6r\u00f6k, M. Toshner, D.P.J. Turner, J. Vekemans, T.L. Villafana, M.E.E. Watson, C.J. Williams, A.D. Douglas, A.V.S. Hill, T. Lambe, S.C. Gilbert, A.J. Pollard, M. Aban, F. Abayomi, K. Abeyskera, J. Aboagye, M. Adam, K. Adams, J. Adamson, Y.A. Adelaja, G. Adewetan, S. Adlou, K. Ahmed, Y. Akhalwaya, S. Akhalwaya, A. Alcock, A. Ali, E.R. Allen, L. Allen, T.C.D.S.C. Almeida, M.P.S. Alves, F. Amorim, F. Andritsou, R. Anslow, M. Appleby, E.H. Arbe-Barnes, M.P. Ariaans, B. Arns, L. Arruda, P. Azi, L. Azi, G. Babbage, C. Bailey, K.F. Baker, M. Baker, N. Baker, P. Baker, L. Baldwin, I. Baleanu, D. Bandeira, A. Bara, M.A.S. Barbosa, D. Barker, G.D. Barlow, E. Barnes, A.S. Barr, J.R. Barrett, J. Barrett, L. Bates, A. Batten, K. Beadon, E. Beales, R. Beckley, S. Belij-Rammerstorfer, J. Bell, D. Bellamy, N. Bellei, S. Belton, A. Berg, L. Bermejo, E. Berrie, L. Berry, D. Berzenyi, A. Beveridge, K.R. Bewley, H. Bexhell, S. Bhikha, A.E. Bhorat, Z.E. Bhorat, E. Bijker, G. Birch, S. Birch, A. Bird, O. Bird, K. Bisnauthsing, M. Bittaye, K. Blackstone, L. Blackwell, H. Bletchly, C.L. Blundell, S.R. Blundell, P. Bodalia, B.C. Boettger, E. Bolam, E. Boland, D. Bormans, N. Borthwick, F. Bowring, A. Boyd, P. Bradley, T. Brenner, P. Brown, C. Brown, C. Brown-O'Sullivan, S. Bruce, E. Brunt, R. Buchan, W. Budd, Y.A. Bulbulia, M. Bull, J. Burbage, H. Burhan, A. Burn, K.R. Buttigieg, N. Byard, I. Cabera Puig, G. Calderon, A. Calvert, S. Camara, M. Cao, F. Cappuccini, J.R. Cardoso, M. Carr, M.W. Carroll, A. Carson-Stevens, Y.d.M. Carvalho, J.A.M. Carvalho, H.R. Casey, P. Cashen, T. Castro, L.C. Castro, K. Cathie, A. Cavey, J. Cerbino-Neto, J. Chadwick, D. Chapman, S. Charlton, I. Chelysheva, O. Chester, S. Chita, J.-S. Cho, L. Cifuentes, E. Clark, M. Clark, A. Clarke, E.A. Clutterbuck, S.L.K. Collins, C.P. Conlon, S. Connarty, N. Coombes, C. Cooper, R. Cooper, L. Cornelissen, T. Corrah, C. Cosgrove, T. Cox, W.E.M. Crocker, S. Crosbie, L. Cullen, D. Cullen, D.R.M.F. Cunha, C. Cunningham, F.C. Cuthbertson, S.N.F. Da Guarda, L.P. da Silva, B.E. Damratoski, Z. Danos, M.T.D.C. Dantas, P. Darroch, M.S. Datoo, C. Datta, M. Davids, S.L. Davies, H. Davies, E. Davis, J. Davis, J. Davis, M.M.D. De Nobrega, L.M. De Oliveira Kalid, D. Dearlove, T. Demissie, A. Desai, S. Di Marco, C. Di Maso, M.I.S. Dinelli, T. Dinesh, C. Docksey, C. Dold, T. Dong, F.R. Donnellan, T. Dos Santos, T.G. dos Santos, E.P. Dos Santos, N. Douglas, C. Downing, J. Drake, R. Drake-Brockman, K. Driver, R. Drury, S.J. Dunachie, B.S. Durham, L. Dutra, N.J.W. Easom, S. van Eck, M. Edwards, N.J. Edwards, O.M. El Muhanna, S.C. Elias, M. Elmore, M. English, A. Esmail, Y.M. Essack, E. Farmer, M. Farooq, M. Farrar, L. Farrugia, B. Faulkner, S. Fedosyuk, S. Felle, S. Feng, C. Ferreira Da Silva, S. Field, R. Fisher, A. Flaxman, J. Fletcher, H. Fofie, H. Fok, K.J. Ford, J. Fowler, P.H.A. Fraiman, E. Francis, M.M. Franco, J. Frater, M.S.M. Freire, S.H. Fry, S. Fudge, J. Furze, M. Fuskova, P. Galian-Rubio, E. Galiza, H. Garlant, M. Gavrila, A. Geddes, K.A. Gibbons, C. Gilbride, H. Gill, S. Glynn, K. Godwin, K. Gokani, U.C. Goldoni, M. Goncalves, I.G.S. Gonzalez, J. Goodwin, A. Goondiwala, K. Gordon-Quayle, G. Gorini, J. Grab, L. Gracie, M. Greenland, N. Greenwood, J. Greffrath, M.M. Groenewald, L. Grossi, G. Gupta, M. Hackett, B. Hallis, M. Hamaluba, E. Hamilton, J. Hamlyn, D. Hammersley, A.T. Hanrath, B. Hanumunthadu, S.A. Harris, C. Harris, T. Harris, T.D. Harrison, D. Harrison, T.C. Hart, B. Hartnell, S. Hassan, J. Haughney, S. Hawkins, J. Hay, I. Head, J. Henry, M. Hermosin Herrera, D.B. Hettle, J. Hill, G. Hodges, E. Horne, M.M. Hou, C. Houlihan, E. Howe, N. Howell, J. Humphreys, H.E. Humphries, K. Hurley, C. Huson, A. Hyder-Wright, C. Hyams, S. Ikram, A. Ishwarbhai, M. Ivan, P. Iveson, V. Iyer, F. Jackson, J. De Jager, S. Jaumdally, H. Jeffers, N. Jesudason, B. Jones, K. Jones, E. Jones, C. Jones, M.R. Jorge, A. Jose, A. Joshi, E.A.M.S. J\u00fanior, J. Kadziola, R. Kailath, F. Kana, K. Karampatsas, M. Kasanyinga, J. Keen, E.J. Kelly, D.M. Kelly, D. Kelly, S. Kelly, D. Kerr, R.d.\u00c1. Kfouri, L. Khan, B. Khozoee, S. Kidd, A. Killen, J. Kinch, P. Kinch, L.D.W. King, T.B. King, L. Kingham, P. Klenerman, F. Knapper, J.C. Knight, D. Knott, S. Koleva, M. Lang, G. Lang, C.W. Larkworthy, J.P.J. Larwood, R. Law, E.M. Lazarus, A. Leach, E.A. Lees, N.-M. Lemm, A. Lessa, 3S. Leung, Y. Li, A.M. Lias, K. Liatsikos, A. Linder, S. Lipworth, S. Liu, X. Liu, A. Lloyd, S. Lloyd, L. Loew, R. Lopez Ramon, L. Lora, V. Lowthorpe, K. Luz, J.C. MacDonald, G. MacGregor, M. Madhavan, D.O. Mainwaring, E. Makambwa, R. Makinson, M. Malahleha, R. Malamatsho, G. Mallett, K. Mansatta, T. Maoko, K. Mapetla, N.G. Marchevsky, S. Marinou, E. Marlow, G.N. Marques, P. Marriott, R.P. Marshall, J.L. Marshall, F.J. Martins, M. Masenya, M. Masilela, S.K. Masters, M. Mathew, H. Matlebjane, K. Matshidiso, O. Mazur, A. Mazzella, H. McCaughan, J. McEwan, J. McGlashan, L. McInroy, Z. McIntyre, D. McLenaghan, N. McRobert, S. McSwiggan, C. Megson, S. Mehdipour, W. Meijs, R.N.\u00c1. Mendon\u00e7a, A.J. Mentzer, N. Mirtorabi, C. Mitton, S. Mnyakeni, F. Moghaddas, K. Molapo, M. Moloi, M. Moore, M.I. Moraes-Pinto, M. Moran, E. Morey, R. Morgans, S. Morris, S. Morris, H.C. Morris, F. Morselli, G. Morshead, R. Morter, L. Mottal, A. Moultrie, N. Moya, M. Mpelembue, S. Msomi, Y. Mugodi, E. Mukhopadhyay, J. Muller, A. Munro, C. Munro, S. Murphy, P. Mweu, C.H. Myasaki, G. Naik, K. Naker, E. Nastouli, A. Nazir, B. Ndlovu, F. Neffa, C. Njenga, H. Noal, A. No\u00e9, G. Novaes, F.L. Nugent, G. Nunes, K. O'Brien, D. O'Connor, M. Odam, S. Oelofse, B. Oguti, V. Olchawski, N.J. Oldfield, M.G. Oliveira, C. Oliveira, A. Oosthuizen, P. O'Reilly, P. Osborne, D.R.J. Owen, L. Owen, D. Owens, N. Owino, M. Pacurar, B.V.B. Paiva, E.M.F. Palhares, S. Palmer, S. Parkinson, H.M.R.T. Parracho, K. Parsons, D. Patel, B. Patel, F. Patel, K. Patel, M. Patrick-Smith, R.O. Payne, Y. Peng, E.J. Penn, A. Pennington, M.P. Peralta Alvarez, J. Perring, N. Perry, R. Perumal, S. Petkar, T. Philip, D.J. Phillips, J. Phillips, M.K. Phohu, L. Pickup, S. Pieterse, J. Piper, D. Pipini, M. Plank, J. Du Plessis, S. Pollard, J. Pooley, A. Pooran, I. Poulton, C. Powers, F.B. Presa, D.A. Price, V. Price, M. Primeira, P.C. Proud, S. Provstgaard-Morys, S. Pueschel, D. Pulido, S. Quaid, R. Rabara, A. Radford, K. Radia, D. Rajapaska, T. Rajeswaran, A.S.F. Ramos, F. Ramos Lopez, T. Rampling, J. Rand, H. Ratcliffe, T. Rawlinson, D. Rea, B. Rees, J. Rein\u00e9, M. Resuello-Dauti, E. Reyes Pabon, C.M. Ribiero, M. Ricamara, A. Richter, N. Ritchie, A.J. Ritchie, A.J. Robbins, H. Roberts, R.E. Robinson, H. Robinson, T.T. Rocchetti, B.P. Rocha, S. Roche, C. Rollier, L. Rose, A.L. Ross Russell, L. Rossouw, S. Royal, I. Rudiansyah, S. Ruiz, S. Saich, C. Sala, J. Sale, A.M. Salman, N. Salvador, S. Salvador, M. Sampaio, A.D. Samson, A. Sanchez-Gonzalez, H. Sanders, K. Sanders, E. Santos, M.F.S. Santos Guerra, I. Satti, J.E. Saunders, C. Saunders, A. Sayed, I. Schim van der Loeff, A.B. Schmid, E. Schofield, G. Screaton, S. Seddiqi, R.R. Segireddy, R. Senger, S. Serrano, R. Shah, I. Shaik, H.E. Sharpe, K. Sharrocks, R. Shaw, A. Shea, A. Shepherd, J.G. Shepherd, F. Shiham, E. Sidhom, S.E. Silk, A.C. da Silva Moraes, G. Silva-Junior, L. Silva-Reyes, A.D. Silveira, M.B.V. Silveira, J. Sinha, D.T. Skelly, D.C. Smith, N. Smith, H.E. Smith, D.J. Smith, C.C. Smith, A. Soares, T. Soares, C. Sol\u00f3rzano, G.L. Sorio, K. Sorley, T. Sosa-Rodriguez, C.M.C.D.L. Souza, B.S.D.F. Souza, A.R. Souza, A.J. Spencer, F. Spina, L. Spoors, L. Stafford, I. Stamford, I. Starinskij, R. Stein, J. Steven, L. Stockdale, L.V. Stockwell, L.H. Strickland, A.C. Stuart, A. Sturdy, N. Sutton, A. Szigeti, A. Tahiri-Alaoui, R. Tanner, C. Taoushanis, A.W. Tarr, K. Taylor, U. Taylor, I.J. Taylor, J. Taylor, R. te Water Naude, Y. Themistocleous, A. Themistocleous, M. Thomas, K. Thomas, T.M. Thomas, A. Thombrayil, F. Thompson, A. Thompson, K. Thompson, A. Thompson, J. Thomson, V. Thornton-Jones, P.J. Tighe, L.A. Tinoco, G. Tiongson, B. Tladinyane, M. Tomasicchio, A. Tomic, S. Tonks, J. Towner, N. Tran, J. Tree, G. Trillana, C. Trinham, R. Trivett, A. Truby, B.L. Tsheko, A. Turabi, R. Turner, C. Turner, M. Ulaszewska, B.R. Underwood, R. Varughese, D. Verbart, M. Verheul, I. Vichos, T. Vieira, C.S. Waddington, L. Walker, E. Wallis, M. Wand, D. Warbick, T. Wardell, G. Warimwe, S.C. Warren, B. Watkins, E. Watson, S. Webb, A. Webb-Bridges, A. Webster, J. Welch, J. Wells, A. West, C. White, R. White, P. Williams, R.L. Williams, R. Winslow, M. Woodyer, A.T. Worth, D. Wright, M. Wroblewska, A. Yao, R. Zimmer, D. Zizi, P. Zuidewind, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, The Lancet 397(10269) (2021) 99\u2013111. doi: https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1195","doi-asserted-by":"crossref","unstructured":"K.J. Ewer, J.R. Barrett, S. Belij-Rammerstorfer, H. Sharpe, R. Makinson, R. Morter, A. Flaxman, D. Wright, D. Bellamy, M. Bittaye, C. Dold, N.M. Provine, J. Aboagye, J. Fowler, S.E. Silk, J. Alderson, P.K. Aley, B. Angus, E. Berrie, S. Bibi, P. Cicconi, E.A. Clutterbuck, I. Chelysheva, P.M. Folegatti, M. Fuskova, C.M. Green, D. Jenkin, S. Kerridge, A. Lawrie, A.M. Minassian, M. Moore, Y. Mujadidi, E. Plested, I. Poulton, M.N. Ramasamy, H. Robinson, R. Song, M.D. Snape, R. Tarrant, M. Voysey, M.E.E. Watson, A.D. Douglas, A.V.S. Hill, S.C. Gilbert, A.J. Pollard, T. Lambe, A. Ali, E. Allen, M. Baker, E. Barnes, N. Borthwick, A. Boyd, C. Brown-O'Sullivan, J. Burgoyne, N. Byard, I.C. Puig, F. Cappuccini, J.-S. Cho, P. Cicconi, E. Clark, W.E.M. Crocker, M.S. Datoo, H. Davies, S.J. Dunachie, N.J. Edwards, S.C. Elias, J. Furze, C. Gilbride, S.A. Harris, S.H.C. Hodgson, M.M. Hou, S. Jackson, K. Jones, R. Kailath, L. King, C.W. Larkworthy, Y. Li, A.M. Lias, A. Linder, S. Lipworth, R.L. Ramon, M. Madhavan, E. Marlow, J.L. Marshall, A.J. Mentzer, H. Morrison, A. No\u00e9, D. Pipini, D. Pulido-Gomez, F.R. Lopez, A.J. Ritchie, I. Rudiansyah, H. Sanders, A. Shea, S. Silk, A.J. Spencer, R. Tanner, Y. Themistocleous, M. Thomas, N. Tran, A. Truby, C. Turner, N. Turner, M. Ulaszewska, A.T. Worth, L. Kingham-Page, M.P.P. Alvarez, R. Anslow, L. Bates, K. Beadon, R. Beckley, A. Beveridge, E.M. Bijker, L. Blackwell, J. Burbage, S. Camara, M. Carr, R. Colin-Jones, R. Cooper, C.J. Cunningham, T. Demissie, C.D. Maso, N. Douglas, R. Drake-Brockman, R.E. Drury, K.R.W. Emary, S. Felle, S. Feng, K.J. Ford, E. Francis, L. Gracie, J. Hamlyn, B. Hanumunthadu, D. Harrison, T.C. Hart, S. Hawkins, J. Hill, E. Howe, N. Howell, E. Jones, J. Keen, S. Kelly, D. Kerr, L. Khan, J. Kinch, S. Koleva, E.A. Lees, A. Lelliott, X. Liu, S. Marinou, J. McEwan, E. Morey, G. Morshead, J. Muller, C. Munro, S. Murphy, P. Mweu, E. Nuthall, K. O'Brien, D. O'Connor, P.J. O'Reilly, B. Oguti, P. Osborne, N. Owino, K. Parker, K. Pfafferott, S. Provstgaard-Morys, H. Ratcliffe, T. Rawlinson, S. Rhead, H. Roberts, K. Sanders, L. Silva-Reyes, C.C. Smith, D.J. Smith, A. Szigeti, T.M. Thomas, A. Thompson, S. Tonks, R. Varughes, I. Vichos, L. Walker, C. White, R. White, X.L. Yao, C.P. Conlon, J. Frater, L. Cifuentes, I. Baleanu, E. Bolam, E. Boland, T. Brenner, B.E. Damratoski, C. Datta, O.E. Muhanna, R. Fisher, P. Galian-Rubio, G. Hodges, F. Jackson, S. Liu, L. Loew, R. Morgans, S.J. Morris, V. Olchawski, C. Oliveria, H. Parracho, E.R. Pabon, A. Tahiri-Alaoui, K. Taylor, P. Williams, D. Zizi, E.H. Arbe-Barnes, P. Baker, A. Batten, C. Downing, J. Drake, M.R. English, J.A. Henry, P. Iveson, A. Killen, T.B. King, J.P.J. Larwood, G. Mallett, K. Mansatta, N. Mirtorabi, M. Patrick-Smith, J. Perring, K. Radia, S. Roche, E. Schofield, R.t.W. Naude, J. Towner, N. Baker, K.R. Bewley, E. Brunt, K.R. Buttigieg, S. Charlton, N.S. Coombes, M.J. Elmore, K. Godwin, B. Hallis, D. Knott, L. McInroy, I. Shaik, K. Thomas, J.A. Tree, C.L. Blundell, M. Cao, D. Kelly, D.T. Skelly, A. Themistocleous, T. Dong, S. Field, E. Hamilton, E. Kelly, P. Klenerman, J.C. Knight, Y. Lie, C. Petropoulos, C. Sedik, T. Wrin, G. Meddaugh, Y. Peng, G. Screaton, E. Stafford, C.V.T.G. the Oxford, T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial, Nat. Med. (2020) doi: https:\/\/doi.org\/10.1038\/s41591-020-01194-5.","DOI":"10.1038\/s41591-020-01194-5"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1200","doi-asserted-by":"crossref","unstructured":"J.R. Barrett, S. Belij-Rammerstorfer, C. Dold, K.J. Ewer, P.M. Folegatti, C. Gilbride, R. Halkerston, J. Hill, D. Jenkin, L. Stockdale, M.K. Verheul, P.K. Aley, B. Angus, D. Bellamy, E. Berrie, S. Bibi, M. Bittaye, M.W. Carroll, B. Cavell, E.A. Clutterbuck, N. Edwards, A. Flaxman, M. Fuskova, A. Gorringe, B. Hallis, S. Kerridge, A.M. Lawrie, A. Linder, X. Liu, M. Madhavan, R. Makinson, J. Mellors, A. Minassian, M. Moore, Y. Mujadidi, E. Plested, I. Poulton, M.N. Ramasamy, H. Robinson, C.S. Rollier, R. Song, M.D. Snape, R. Tarrant, S. Taylor, K.M. Thomas, M. Voysey, M.E.E. Watson, D. Wright, A.D. Douglas, C.M. Green, A.V.S. Hill, T. Lambe, S. Gilbert, A.J. Pollard, J. Aboagye, J. Alderson, A. Ali, E. Allen, L. Allen, R. Anslow, C.V. Arancibia-C\u00e1rcamo, E.H. Arbe-Barnes, M. Baker, P. Baker, N. Baker, I. Baleanu, E. Barnes, L. Bates, A. Batten, K. Beadon, R. Beckley, A. Beveridge, K.R. Bewley, E.M. Bijker, L. Blackwell, C.L. Blundell, E. Bolam, E. Boland, N. Borthwick, A. Boyd, T. Brenner, P. Brown, C. Brown-O'Sullivan, E. Brunt, J. Burbage, K.R. Buttigieg, N. Byard, I. Cabrera Puig, S. Camara, M. Cao, F. Cappuccini, M. Carr, M.W. Carroll, J. Chadwick, I. Chelysheva, J.-S. Cho, L. Cifuentes, E. Clark, R. Colin-Jones, C.P. Conlon, N.S. Coombes, R. Cooper, W.E.M. Crocker, C.J. Cunningham, B.E. Damratoski, M.S. Datoo, C. Datta, H. Davies, T. Demissie, C. Di Maso, D. DiTirro, T. Dong, F.R. Donnellan, N. Douglas, C. Downing, J. Drake, R. Drake-Brockman, R.E. Drury, S.J. Dunachie, O.E. Muhanna, S.C. Elias, M.J. Elmore, K.R.W. Emary, M.R. English, S. Felle, S. Feng, C.F. Da Silva, S. Field, R. Fisher, K.J. Ford, J. Fowler, E. Francis, J. Frater, J. Furze, P. Galian-Rubio, H. Garlant, K. Godwin, G. Gorini, L. Gracie, G. Gupta, E. Hamilton, J. Hamlyn, B. Hanumunthadu, S.A. Harris, D. Harrison, T.C. Hart, S. Hawkins, J.A. Henry, G. Hodges, S.H.C. Hodgson, M.M. Hou, E. Howe, N. Howell, B. Huang, H. Humphries, P. Iveson, S. Jackson, F. Jackson, S. Jauregui, K. Jeffery, E. Jones, K. Jones, R. Kailath, J. Keen, S. Kelly, D. Kelly, E. Kelly, D. Kerr, L. Khan, B. Khozoee, A. Killen, J. Kinch, T.B. King, L. King, L. Kingham-Page, P. Klenerman, J.C. Knight, D. Knott, S. Koleva, C.W. Larkworthy, J.P.J. Larwood, E.A. Lees, A. Lelliott, S. Leung, Y. Li, A.M. Lias, S. Lipworth, S. Liu, L. Loew, R. Lopez Ramon, G. Mallett, K. Mansatta, N.G. Marchevsky, S. Marinou, E. Marlow, J.L. Marshall, P. Matthews, J. McEwan, J. McGlashan, L. McInroy, G. Meddaugh, A.J. Mentzer, N. Mirtorabi, E. Morey, R. Morgans, S.J. Morris, H. Morrison, G. Morshead, R. Morter, N. Moya, E. Mukhopadhyay, J. Muller, C. Munro, S. Murphy, P. Mweu, A. No\u00e9, F.L. Nugent, E. Nuthall, K. O'Brien, D. O'Connor, D. O'Donnell, B. Oguti, V. Olchawski, C. Oliveria, P.J. O'Reilly, P. Osborne, N. Owino, K. Parker, H. Parracho, M. Patrick-Smith, Y. Peng, E. Penn, M.P. Peralta Alvarez, J. Perring, C. Petropoulos, K. Pfafferott, D. Pipini, D. Phillips, P. Proud, S. Provstgaard-Morys, D. Pulido, K. Radia, D. Rajapaksa, F. Ramos Lopez, H. Ratcliffe, T. Rawlinson, E.R. Pabon, S. Rhead, A.J. Ritchie, H. Roberts, S. Roche, I. Rudiansyah, S. Salvador, H. Sanders, K. Sanders, I. Satti, A. Schmid, E. Schofield, G. Screaton, C. Sedik, I. Shaik, H.R. Sharpe, A. Shea, S. Silk, L. Silva-Reyes, D.T. Skelly, C.C. Smith, D.J. Smith, A.J. Spencer, E. Stafford, A. Szigeti, A. Tahiri-Alaoui, R. Tanner, I.J. Taylor, K. Taylor, R. te Water Naude, Y. Themistocleous, A. Themistocleous, M. Thomas, T.M. Thomas, A. Thompson, L. Tinh, A. Tomic, S. Tonks, J. Towner, N. Tran, J.A. Tree, A. Truby, C. Turner, N. Turner, M. Ulaszewska, R. Varughese, I. Vichos, L. Walker, M. Wand, C. White, R. White, P. Williams, A.T. Worth, C.V.T.G. the Oxford, Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses, Nat. Med. (2020) doi: https:\/\/doi.org\/10.1038\/s41591-020-01179-4.","DOI":"10.1038\/s41591-021-01372-z"},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1205","unstructured":"Pharmaphorum, COVID-19 vaccine cleared in UK, dosing to start next week. https:\/\/pharmaphorum.com\/news\/az-covid-19-vaccine-cleared-in-uk-dosing-to-start-next-week\/. (Accessed 8 January 2021)."},{"key":"10.1016\/j.ijbiomac.2021.01.076_bb1210","unstructured":"Covaxin - India's first indigenous COVID-19 vaccine. https:\/\/www.bharatbiotech.com\/covaxin.html. (Accessed 8 January 2021)."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813021001069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813021001069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:42:53Z","timestamp":1758876173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813021001069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":244,"alternative-id":["S0141813021001069"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.01.076","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.01.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}